Back

OBD

6.32%
NEUTRAL

Oxford BioDynamics' UK Lab Accredited by UKAS for EpiSwitch Testing

Why we think this is neutral

The RNS announcement is a general update on the company's UK lab receiving UKAS accreditation to run its EpiSwitch clinical tests. While this is a positive operational milestone, it does not contain any of the mandatory news types that would warrant a stronger sentiment score.

Key Points

  • OBD's UK facility in Oxford has been accredited by UKAS as a clinical lab under ISO 15189
  • Clinical validation of EpiSwitch CiRT has been completed in the Oxford lab
  • All orders for CiRT and PSE in the UK and Europe will now be processed within the UK lab

Summary

The diagnostics company has received accreditation for its UK lab to run its proprietary EpiSwitch tests, improving turnaround times for customers in the region.

Oxford BioDynamics Plc (OBD) has announced that its UK facility in Oxford has been accredited by the United Kingdom Accreditation Service (UKAS) as a clinical laboratory under the ISO 15189 standard. This allows the company to process all orders for its EpiSwitch CiRT and PSE tests in the UK and Europe within its own lab, reducing turnaround times for customers. The company has also successfully completed the clinical validation of its EpiSwitch Checkpoint Inhibitor Response Test (CiRT) in the Oxford lab.

Key Dates

April 1, 2025
Completion of UK lab commissioning
GENERAL UPDATE